Inflammation and Coronary Artery Disease: Role of AT1-Receptor Antagonism
NCT00274144
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Hypertension
Coronary Arteriosclerosis
Interventions
DRUG:
telmisartan 40 mg
DRUG:
placebo 40 mg
Sponsor
Boehringer Ingelheim